NextPlat (NASDAQ:NXPL) Raised to “Strong-Buy” at Litchfield Hills Research

NextPlat (NASDAQ:NXPL) was upgraded by stock analysts at Litchfield Hills Research to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Separately, Weiss Ratings upgraded NextPlat from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $11.00.

NextPlat Price Performance

NXPL stock opened at $6.48 on Wednesday. The firm has a 50 day simple moving average of $6.35 and a two-hundred day simple moving average of $5.93. The stock has a market cap of $17.56 million, a PE ratio of -1.50 and a beta of 1.90. NextPlat has a one year low of $3.38 and a one year high of $11.10. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.56 and a quick ratio of 2.12.

NextPlat (NASDAQ:NXPL) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.42) earnings per share for the quarter. NextPlat had a negative net margin of 23.14% and a negative return on equity of 58.05%. The company had revenue of $9.86 million for the quarter.

Institutional Investors Weigh In On NextPlat

An institutional investor recently bought a new stake in NextPlat stock. Citadel Advisors LLC purchased a new position in NextPlat Corp. (NASDAQ:NXPL) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 48,176 shares of the company’s stock, valued at approximately $40,000. Citadel Advisors LLC owned about 0.19% of NextPlat as of its most recent SEC filing. Hedge funds and other institutional investors own 1.30% of the company’s stock.

NextPlat Company Profile

NextPlat Corp operates as a healthcare and e-commerce company in Europe, North America, South America, the Asia and Pacific, and Africa. The company operates full-service retail specialty services pharmacies that provides prescription pharmaceuticals prescription pharmaceuticals, third-party administration, risk and data management services, compounded medications, tele-pharmacy services, anti-retroviral medications, medication therapy management, contracted pharmacy services, and health practice risk management to healthcare organizations and providers, as well as supplies prescription medications to long-term care facilities.